Analyst consensus rating
Pyxis Oncology Analyst Rating: Strong Buy
PYXS is rated Strong Buy by 9 analysts with a $7.22 target. As of 2026-08-29.
Direct answer
Pyxis Oncology's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.22.
Forecast evidence checked August 29, 2026.
Get free Pyxis Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.23
- Average price target
- $7.22
- High price target
- $12.00
- Low price target
- $5.00
- Low target gap
- +54.8%
- Target upside
- +123.6%
- High target gap
- +271.5%
- Target range width
- 216.7%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Pyxis Oncology?
Pyxis Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $7.22.
How far are Pyxis Oncology's low and high targets from the recorded price?
The low target implies +54.8%, while the high target implies +271.5%.
How many analysts are included in Pyxis Oncology's consensus?
The verified consensus includes 9 analysts.
How is Pyxis Oncology's target upside or downside calculated?
The average target of $7.22 is divided by the recorded price of $3.23, then one is subtracted to produce +123.6%. This does not guarantee a future return.
When was Pyxis Oncology's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.